Clinical trials: Allogeneic Stem-Cell Transplant
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
The study "GALAXY33" is an open-label, prospective, nonrandomized, one arm phase I clinical trial in which patients with relapsed AML after allogeneic hematopoietic stem cell transplantation will be transplanted with CD33-deleted…
- Trial name
- GALAXY33 (NCT05662904)
- Testing
- Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin
- Where
- 2 sites in Germany
- Volunteers
- 12 people
- Sponsor
- German Cancer Research Center
Failure of Bone Marrow Graft
Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant
This phase I/II clinical trial will test the safety and the efficacy of post transplant administration of plerixafor in enhancing hematological recovery in humans.
- Trial name
- NCT01280955
- Testing
- Plerixafor
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Mitchell Horwitz, MD
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria
Nonmyeloablative Allogeneic Transplant
Allogeneic transplant from a matched sibling for the treatment of a variety of illnesses including bone marrow failure states, leukemias, myelodysplastic or myeloproliferative syndromes, lymphoma, or myeloma using a…
- Conditions
- Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
- Trial name
- Mini-allo (NCT01272817)
- Testing
- Nonmyeloablative Allogeneic Transplant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Scripps Health
Acute Myeloid Leukemia
A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation
A Trial to Evaluate the Safety and Efficacy of iNK in the Treatment of Subjects for Preventing Recurrence of Acute Myeloid Leukemia After Allogeneic Blood Stem Cell Transplantation.
- Trial name
- NCT06441084
- Testing
- NCR300 injection
- Volunteers
- 15 people
- Sponsor
- Nuwacell Biotechnologies Co., Ltd.
Acute Leukemia, Myelodysplastic Syndrome
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
In an effort to reduce graft versus host disease (GVHD) and enhance graft versus leukemia (GVL) effect post allogenic hematopoietic stem cell transplantation (AHSCT), recent research has focused on host immune cell depletion.
- Conditions
- Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
- Trial name
- NCT06265584
- Testing
- ATG dosing platform when combined with standard tacrolimus and mini methotrexate
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Alabama at Birmingham
Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes
Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
This is a single-center randomized open-label phase II clinical trial to compare relapse prophylaxis with sorafenib and observation after graft-versus-host disease prophylaxis with post-transplantation bendamustine and…
- Conditions
- Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Myeloproliferative Neoplasm
- Trial name
- SoraGVL (NCT06532084)
- Testing
- Sorafenib
- Where
- Russia
- Volunteers
- 88 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Chronic Granulomatous Disease
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
Background: CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used.
- Trial name
- NCT03910452
- Testing
- Busulfan, Alemtuzumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hematological Diseases, Allogeneic Stem Cell Transplantation
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation
The primary objective of this study is to evaluate the efficacy and safety profile of itraconazole as in primary prophylaxis The second objective of this study is to find the difference between long-term versus short-term…
- Trial name
- NCT01160952
- Testing
- itraconazole
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
Epidermolysis Bullosa
Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa
RATIONALE: In animal models, stem cells have been shown to home to the skin and repair the biochemical and structural abnormalities associated with recessive dystrophic epidermolysis bullosa (RDEB) (collagen 7 deficiency).
- Trial name
- NCT00478244
- Testing
- busulfan, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia
Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative option for patients with acute myeloid leukemia (AML).
- Trial name
- ELIT-AML01 (NCT03597321)
- Testing
- prophylactic donor lymphocyte infusion (DLI)
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Institut Paoli-Calmettes
Hematological Malignancies, Myelodysplastic Syndrome
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
The goal of this clinical research study is to learn if the combination of rabbit anti-thymocyte globulin (Thymoglobulin®), sirolimus (Rapamune®), and mycophenolate mofetil (Cellcept®) can help to prevent graft versus host…
- Conditions
- Hematological Malignancies, Myelodysplastic Syndrome, Leukemia, Lymphoma
- Trial name
- NCT00506948
- Testing
- Mycophenolate Mofetil (MMF), Thymoglobulin, Sirolimus
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelocytic Leukemia, Myelodysplastic Syndromes
Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Allo - hematopoietic stem cell transplantation is currently the only way to cure myelodysplastic syndrome /acute leukemia . The existing experimental results showed that decitabine and 5-azacytidine up-regulated the expression of…
- Trial name
- NCT01809392
- Testing
- decitabine
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma
Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma
The purpose of the study is to determine the safety of MLN9708 as maintenance therapy following allogeneic stem cell transplant in patients with multiple myeloma.
- Trial name
- NCT02168101
- Testing
- MLN9708
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- SCRI Development Innovations, LLC
Primary Myelofibrosis, Secondary Myelofibrosis
Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
This pilot clinical trial studies the side effects and best dose of ruxolitinib phosphate when given together with chemotherapy before and after a donor stem cell transplant in treating patients with myelofibrosis.
- Trial name
- NCT02917096
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
HIV Infection
Immune Therapy and Analytical Treatment Interruption in HIV+ Participants Who Received an Allogeneic Stem Cell Transplantation
The availability of antiretroviral therapy (cART) for HIV-1 infection has led to a reduction in morbidity in patients with chronic HIV infection.
- Trial name
- ITATI (NCT04720742)
- Testing
- Analytical Treatment Interruption + bNAbs infusion
- Where
- 4 sites in Italy, Netherlands and 1 more
- Sponsor
- IrsiCaixa
Aggressive Non-hodgkin Lymphoma (aNHL), Lymphoma, B-Cell
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy
A prospective Phase II clinical study to assess the efficacy and toxicity of high dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (allo- or autoSCT) as treatment of primary progressive and relapsed…
- Conditions
- Aggressive Non-hodgkin Lymphoma (aNHL), Lymphoma, B-Cell, Lymphoma, T-Cell
- Trial name
- NCT04121507
- Testing
- High dose chemotherapy before allogeneic stem cell transplantation (alloSCT), Bone marrow histology, clinical and laboratory parameters
- Where
- 13 sites in Germany
- Volunteers
- 60 people
- Sponsor
- GWT-TUD GmbH
Cytomegalovirus Infections
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
The purpose of this trial is to determine if preemptive therapy with oral valganciclovir is as effective as intravenous ganciclovir in clearing cytomegalovirus (CMV) viremia as determined by quantitative CMV polymerase chain…
- Trial name
- NCT00241345
- Testing
- Valganciclovir, Ganciclovir
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Washington University School of Medicine
Philadelphia Chromosome-positive Chronic Myelocytic Leukemia
Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion
Allogeneic stem cell transplantation, the only known curative modality for CML, was abandoned in recent years for a very effective and much less toxic targeted therapy with the tyrosine kinase inhibitors (TKIs).
- Trial name
- NCT00966810
- Testing
- Stem cell transplantation
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rambam Health Care Campus
Multiple Myeloma
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT).
- Trial name
- NCT03127761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplant
- Where
- United States
- Volunteers
- 544 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Multiple Myeloma and Plasma Cell Neoplasm
Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00802568
- Testing
- anti-thymocyte globulin, busulfan, fludarabine phosphate
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Institut Paoli-Calmettes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.